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Background: Psoriatic arthritis (PsA) is a distinct inflammatory arthritis occurring in 30% of psoriasis patients.
There is a high prevalence of undiagnosed PsA in psoriasis patients; therefore, identifying soluble biomarkers for
PsA could help in screening psoriasis patients for appropriate referral to a rheumatologist. Potential PsA biomarkers
likely originate in sites of inflammation, such as the skin, and subsequently enter systemic circulation. Our goal was
to identify candidate PsA biomarkers by comparing the proteome of skin biopsies obtained from patients with PsA
to that from patients with psoriasis without PsA.
Methods: Skin biopsies were obtained from involved and uninvolved skin of 10 PsA and 10 age/gender-matched
psoriasis patients without PsA (PsC). Using strong cation exchange chromatography, followed by label-free quantitative
tandem mass spectrometry, we characterized the proteomes of pooled skin samples. Extracted ion current intensities
were used to calculate protein abundance ratios, and these were utilized to identify differentially regulated proteins.
Results: Forty-seven proteins were elevated in PsA-derived skin compared to PsC-derived skin. Selected reaction
monitoring assays were developed to quantify these potential PsA markers in individual skin samples, and 8 markers
were confirmed in an independent sample set. ITGB5 and POSTN were measured in serum samples from 33 PsA and
15 PsC patients, using enzyme-linked immunosorbent assays. ITGB5 was significantly elevated in PsA serum (P < 0.01),
and POSTN showed a trend. ITGB5 and POSTN correlated significantly in both patient groups (r = 0.472, P < 0.001).
Conclusion: Proteomic analysis of PsA and PsC skin identified eight new candidate biomarkers. These markers need
to be validated with a larger and independent cohort, in order to delineate their clinical utility in PsA patients. These
proteins may also uncover unknown aspects of PsA pathobiology.
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Psoriatic arthritis (PsA) is a distinct inflammatory arth-
ritis, which takes its name from its association with the
cutaneous, autoimmune inflammatory disease, psoriasis.
It occurs in 30% of psoriasis patients and has a predicted
prevalence of up to 1% in the general population. PsA is
a complex, potentially disabling musculoskeletal disorder
often arising early in age. Patients with PsA have an* Correspondence: vchandra@uhnresearch.ca
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unless otherwise stated.increased risk for a spectrum of co-morbidities, such as
obesity, metabolic syndrome, diabetes and cardiovascular
disease [1-3]. The diagnosis of PsA presents a challenge,
largely due to its heterogeneous clinical presentation [4,5];
however, early diagnosis and prognosis of PsA is essential
for prevention of joint damage and disability [6].
The key to early diagnosis is a better recognition of PsA
in patients with psoriasis, since its presence indicates a
high risk for current or future development of PsA [3].
Soluble biomarkers represent an ideal means for screening
patients for PsA. With improvements in high-throughput
genomic platforms, a number of putative markers, ranging
from susceptibility genes to mRNA profiles have been
proposed [7-11]; however there exists no single or panelhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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research, therefore, focuses on the discovery and validation
of PsA biomarkers [7,12-14]. Identifying these factors
would not only facilitate diagnosis and prognosis of PsA,
but also provide further insight into disease pathogenesis.
Mass spectrometry (MS)-based quantitative proteomic
approaches are well-suited for the discovery of protein
mediators and biomarkers of disease [15,16]. Specifically,
label-free quantification (LFQ) methods have been recently
optimized, where quantification is based on the differential
peak intensity [extracted ion current (XIC)] of the peptides
in each MS scan [17,18]. Such experiments often result
in tens to hundreds of candidate biomarkers, therefore, in
this context of biomarker discovery, high-throughput mass
spectrometry-based proteomics is a powerful tool for
obtaining disease-specific proteome profiles of biological
materials [19]. While human plasma represents a diverse
proteome and is an excellent source of potential disease
markers, proteins secreted by tissues are diluted in blood,
and are often undetectable by current MS methods [19].
Much interest has been given to the analysis of proximal
fluids and tissues, such as synovial fluid and skin [19-21].
Cutaneous psoriasis develops simultaneously or precedes
the onset of PsA in up to 90% of PsA patients, and in order
to move forward in the search for PsA screening bio-
markers, we must consider the preceding cutaneous
psoriasis stage in PsA patients. Therefore, hypothesizing
that there are differences in the skin proteome of patients
with PsA compared to those with psoriasis but without
PsA (PsC), comparative analysis of skin between these
two patient groups represents a reasonable experimental
workflow. In a pilot study, our group demonstrated that
proteins elevated in the inflamed skin, are likewise up-
regulated at the serum level, and may serve as putative
markers of psoriasis [22].
In the current study, we performed label-free quantita-
tion of skin proteins from PsA and PsC patients. Using
selected reaction monitoring assays (SRM) we confirmed
the elevation of some proteins in an independent set of
samples from patients with PsA. Following a small-scale
validation in serum using enzyme-linked immunosorbent
assays (ELISA), we confirmed a significant elevation of β5
Integrin (ITGB5) in the serum of PsA patients. Periostin
(POSTN) also showed a similar trend. These proteins may
serve as potential PsA biomarkers and also shed new light
into the pathogenesis of PsA.
Results
Delineating the PsA skin proteome
Our LC-MS/MS analysis yielded 1922 quantifiable proteins
(Additional file 1: Table S1). Student’s t-tests, and a false
discovery rate (FDR) threshold of 0.2, were utilized to iden-
tify upregulated proteins between the PsA and PsC lesional
groups (PsA L, and PsC L, respectively). This comparativeanalysis generated a total of 62 proteins (Additional file 2:
Table S2). Generally, these proteins exhibited a fold change
ratio above 4.0. Comparison between PsA and PsC non-
lesional skin (PsA N, and PsC N, respectively), at the
same FDR, demonstrated elevated expression of 131
proteins (Additional file 2: Table S2). By comparing the
proteins identified from the two independent analyses
(PsA L vs PsC L, and PsA N vs. PsC N), only 7 of these
proteins were common (Additional file 2: Table S2). These
were PSME3, C1QC, RENBP, GRHPR, POLE, POSTN,
and IGLV3-21.
Since our scope was to identify potential biomarkers
present in PsA skin, we decided to focus on the 62 pro-
teins overexpressed in the lesional PsA skin, which
included the seven proteins elevated in non-lesional
skin, since they are more likely to represent mediators
and potential biomarkers of PsA. We further focused on
proteins displaying strong expression in skin, bone, and
immune regulatory cells, and excluded immunoglobulins,
unknown proteins and high abundance serum proteins
from further analysis. Additional file 3: Table S3 presents
the final list of 47 proteins, corresponding fold changes
(FC) between PsA and PsC samples, P-Values and FDR
values. These were then assessed and quantified, using a
multiplexed selected reaction monitoring assay, in individ-
ual skin samples included in the discovery set (Set I), as
well as in an independent set of 10 samples (Set II).
SRM Verification of putative markers in individual skin
samples
We developed a multiplexed SRM assay to verify the
differences in protein expression between lesional PsA
and PsC skin. Assays were developed for 47 peptides
representative of the 47 proteins with increased expres-
sion in the skin of PsA patients, as well as 4 peptides
representing 2 housekeeping proteins (ACTB, TUBB)
(Additional file 4: Table S4). Consistent with our LC-MS/
MS analysis of the pooled samples, overexpression of 12
out of the 47 proteins was also verified in the individual
PsA lesional skin samples (Set I), when compared to
lesional PsC samples. Each sample consisted of two tech-
nical replicates. The mean fold change of each confirmed
protein in the lesional and non-lesional PsA and PsC skin
samples, as well as the associated P-values are depicted in
Table 1. The proteins included C16ORF62, SNCA, LZIC,
SRP14, ITGB5, POSTN, SRPX, FHL1, PPP2R4, CPN2,
GPS1, and PAFAH1B2. The distribution of these, and the
housekeeping proteins across the Set I skin samples, are
represented in Additional file 5: Figure S1.
Additionally, we further confirmed the elevation of 8
of the aforementioned 12 proteins, in an independent
set of 5 PsA, and 5 PsC lesional skin samples (Set II). In
this case, we utilized a heavy-labeled peptide in order to
obtain the absolute concentration of these peptides in
Table 1 Fold change (FC) of candidate markers in Set I and Set II* skin following SRM quantification
Set I Set II
Lesional Non-lesional Lesional
Protein name PsA:PsC FC** P-value*** PsA:PsC FC P-value PsA:PsC FC P-value
CPN2 17.4 <0.001 2.4 0.030 1.9 0.032
GPS1 6.0 0.014 1.2 0.385 17.9 0.008
C16ORF62 6.0 <0.001 5.3 0.007 3.9 0.667
FHL1 4.6 <0.001 3.1 0.021 2.2 0.016
SRPX 3.8 0.043 3.3 0.014 5.0 0.008
SNCA 3.6 <0.001 1.7 0.089 3.8 0.095
POSTN 3.5 0.001 2.8 0.013 7.5 0.032
PAFAH1B2 3.3 0.004 2.0 0.104 0.8 0.667
SRP14 3.0 0.019 1.3 0.570 2.4 0.016
ITGB5 2.7 0.006 3.5 0.017 4.2 0.032
PPP2R4 2.2 0.043 2.0 0.678 3.9 0.008
LZIC 2.0 0.036 1.6 0.212 1.2 0.413
*The description of Set I and Set II are given in the experimental methods section.
**Fold change (FC) represents the ratio of means of 10 (Set I) or 5 (Set II) skin samples per group. Data are based on normalized XIC ratios, as described in the
experimental methods section. PsA, psoriatic arthritis; PsC, cutaneous psoriasis.
***P-Values were calculated using the non-parametric Mann-Whitney U test.
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SRPX, FHL1, PPP2R4, CPN2, and GPS1. The mean fold
changes and P-values corresponding to each protein
from set II are also depicted in Table 1. Additional file 6:
Figure S2 shows the distribution of the 8 proteins across
the Set II skin samples, as well as of the housekeeping
proteins. Since only 8 proteins were confirmed in the
independent sample set, we decided to consider for
further analyses only these 8 potential markers.
Small-scale ELISA validation in serum
To validate the possible expression of markers in serum
of PsA patients, we measured the levels of ITGB5 and
POSTN in the serum of 15 PsC and 33 PsA patients. As
shown in Figure 1, ITGB5 was significantly elevated in PsA,Figure 1 Distribution of markers across the PsA and PsC serum sets. S
by ELISA. Dots represent serum samples from individual subjects; thin horizon
represents the ratio of the mean concentration values corresponding to 33 Ps
PsA, Psoriatic Arthritis; PsC, Cutaneous Psoriasis.when compared to PsC patients (1.19 ± 0.5 compared to
0.77 ± 0.6; p < 0.01). The concentration of POSTN was not
significantly different between the two groups (p > 0.05),
but the levels in PsA serum showed an increasing trend,
when compared to PsC serum (17.71 ± 6.4 compared to
14.53 ± 6.2). The mean FC and distribution of POSTN and
ITGB5 in the PsA and PsC serum, are represented in
Figure 1. We were unable to measure SRP14, SRPX, FHL1,
PPP2R4, CPN2, and GPS1, due to unavailability of ELISA
kits, antibodies, or protein standards.
Correlation amongst biomarkers
Spearman’s rank correlation coefficient was used to
assess the correlation amongst markers for the PsA, and
PsC serum groups. ITGB5 correlated significantly withmall-scale validation of ITGB5 (A) and POSTN (B) in PsA and PsC serum
tal lines depict the mean, and vertical lines the standard deviation; FC
A and 15 PsC serum samples. ** indicates P < 0.01; ns: non-significant.
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and in PsA serum (Spearman r = 0.433, P = 0.012). Figure 2
displays the correlation between POSTN and ITGB5 in all
samples (Spearman r = 0.472, P < 0.001).Discussion
Recent advances in mass spectrometry-based proteomics
facilitated the identification of putative novel biomarkers
and mediators from a variety of tissues, and for various
clinical applications [15,16,23]. In this study, we conducted
high-throughput quantitative proteomics to identify differ-
entially expressed proteins between skin derived from
PsA and PsC patients. According to our filtering criteria,
forty-seven proteins were elevated in the PsA group, when
compared to the PsC group. Eight proteins were verified
using a multiplexed selected reaction monitoring assay, in
an independent skin sample set. None of these potential
markers has been described before in the context of PsA
or psoriasis. Since serum measurement of these proteins
using SRMs is not efficient due to the high complexity
of the fluid [18], we utilized available enzyme-linked
immunosorbent assays to measure two biomarker can-
didates in serum (ITGB5, and POSTN).
Cumulative evidence strongly supports the involvement
of Interleukin (IL)-23/IL-17 axis in the pathogenesis of
PsA, and a number of compounds that target components
of these pathways have been recently used in PsA clinical
trials. IL-23 acts synergistically with IL-6 and TGF-β to
promote rapid Th17 development and IL-17 release
[24,25], which, in turn, plays a central role in sustaining
chronic inflammation [24]. Both POSTN and ITGB5
have been implicated with this pathway.Figure 2 Correlation between ITGB5 and POSTN across the PsA and PsC
r indicates the Spearman’s rank correlation coefficient.Periostin is a matricellular protein belonging to the fasci-
lin family [26]. It interacts with several integrin molecules
on cell surfaces, one of which is α5β5 Integrin, and provides
signals for tissue development and remodeling [27]. More
specifically, it is thought that POSTN interacts with α5β5 to
induce pro-inflammatory cytokine production via the Akt/
NF-κB signaling pathway [28]. In support of this, deficiency
of POSTN or inhibition of α5 integrin (ITGA5) prevented
development or progression of skin inflammation in an
atopic dermatitis mouse model [28]. Additionally, POSTN
has been shown to also act on immune cells, leading to
their enhanced transmigration, chemotaxis, and adhesion
[29], all of which further implicate this molecule in inflam-
matory processes relevant to PsA.
Apart from acting as a POSTN ligand (along with
ITGA5), ITGB5 has also been implicated in rheumatoid
arthritis, where it serves as a ligand for Cyr61 [30]. Cyr61
is a molecule secreted by fibroblast-like synoviocytes in
the joint, and stimulates IL-6 production via ITGA5-
ITGB5/Akt/NF-κB signaling pathway [29]. As described
earlier, IL-6, along with IL-23 and TGB-β, trigger Th17
differentiation and IL-17 production [24,25] in inflamma-
tory processes, including PsA. Based on this data, we
suggest that POSTN and ITGB5 are attractive molecules
to investigate further as PsA biomarkers.
Following a small-scale serum validation of POSTN and
ITGB5, we determined that only ITGB5 was significantly
elevated in PsA serum, although POSTN also showed a
trend. Additionally, Spearman correlation showed that
serum ITGB5 correlates well with POSTN (r = 0.472,
p < 0.001), which indicates that these two markers may,
in the future, be used as part of a panel of markers to
screen for PsA in PsC patients.serum sets. Dots represent serum samples from individual subjects.
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here has some limitations. First, pooling of the skin
samples in the discovery phase has advantages and dis-
advantages. While pooling allows for a more extensive
coverage of disease heterogeneity, by increasing the
likelihood of identifying proteins that are otherwise
undetectable in some individual samples, it may also mask
meaningful discrepancies among the different individual
skin proteomes [19,31]. To minimize this effect, samples
were pooled to obtain two distinct pools in both, PsA and
PsC groups. Additionally, all pool-derived candidates were
further examined in all individual samples using a targeted
and more sensitive mass spectrometry technique. As our
results indicate, the correlation between the discovery data
and SRM data is not ideal, whereby only 12 proteins were
verified in the discovery set. This is due in part, to the
“pooling” effects previously discussed. Our SRM data from
individual samples identified several skin samples that had
prominently higher protein concentrations. These samples
most probably affected (increased) the final concentration
of proteins in the pooled samples, which were used for
our initial selection of candidates. Thus, analysis of indi-
vidual samples via SRM assay allowed for elimination of
such artifacts.
Second, the identified markers were only tested on a
small number of serum samples (n = 48), and only 20 of
these were distinct from the Set I and Set II sample sets.
Therefore, to assess their accuracy in serum, these
markers still need to be tested in a large-scale verification
study. In addition, as discussed previously, only two of the
existing eight proposed markers have been investigated in
serum due to the lack of ELISAs or antibodies for the rest.
Hence, strategies to enable measurement of the remainder
of the markers will be employed in the future.
Finally, the 47 proteins we investigated using SRM, repre-
sent few of the candidates we have presently identified. Pro-
teins that were elevated in non-lesional skin also represent
interesting candidates, and must be measured in the future.
Taken together, our current observations are consistent
with the notion that label-free quantitative LC-MS/MS
can be utilized to quantify proteins in tissues, which can
then be shed into the circulation and serve as serum
markers of PsA. Further studies to validate these findings
are underway, in a larger and independent serum cohort.
Investigating these proposed markers further, may not only
result in the identification of PsA screening biomarkers,





Samples were collected with informed consent after re-
search ethics board approval from the University HealthNetwork, Toronto, Canada. For the discovery phase, skin
biopsies were obtained from 10 cases with PsA (6 males,
4 females; age range 38-73 years) and 10 PsC patients
(6 males, 4 females; age range 28-77 years) (Set I). PsA
patients had psoriasis and satisfied the CASPAR classifica-
tion criteria [32], while the PsC patients were assessed
by a rheumatologist, to exclude PsA. Patients were not
undergoing treatment with methotrexate (MTX) or anti-
TNF agents. One 6mm punch biopsy was obtained from
unaffected (non-lesional) skin, and one from affected
(lesional) skin from each PsA and PsC patient, amounting
to a total of 40 samples.
For the verification (quantification) phase, an independ-
ent set of skin samples was obtained from 5 PsA patients
(all males; age range 49-63 years), and 5 PsC patients
(3 males, 2 females; age range 49-67 years) (Set II). Inclu-
sion criteria were the same as described above.
For the small-scale validation, serum samples were
obtained from 33 PsA patients (22 males, 11 females;
age range 21-76 years), and 15 PsC controls (9 males, 6
females, age range 28-77 years). Inclusion criteria were
the same as described above.
Pre-analytical sample processing
Skin samples were snap-frozen in liquid nitrogen and
stored at -80°C until use. Samples were suspended in
0.05% RapiGest (Waters, Milford, MA, USA) buffer, and
the tissue was homogenized and sonicated for protein
extraction. The tissue lysates were spun at 11,000g and
total protein was measured by the Bradford assay (Pierce
Biotechnology, Rockford, IL, USA), in the resulting super-
natants. Equal protein amounts from each sample were
pooled to create eight different pools of five samples each
[2 PsA lesional (PsA L) vs. 2 PsA non-lesional (PsA N) vs.
2 PsC lesional (PsC L) vs. 2 PsC non-lesional (PsC N)].
Proteins in each pool were denatured and reduced with
5 mM dithiothreitol at 60°C for 45 minutes and alky-
lated with 15 mM iodoacetamide, in the dark, at room
temperature, for 45 minutes. Sequencing grade trypsin
(Promega, Madison, WI, USA) was added in a 1:50 (tryp-
sin: protein) ratio, and allowed to digest for 18 hours
at 37°C. Trifluoroacetic acid (1%) was added to cleave
RapiGest and inhibit trypsin activity, and samples were
centrifuged at 11,000g for 20 minutes prior to high
performance liquid chromatography (HPLC) using strong
cation exchange (SCX), to reduce peptide mixture com-
plexity. During the initial stages of SCX, buffer blanks
were run after each sample, and the resulting fractions
were assessed for peptide carryover; apart from peptides
corresponding to a few high abundance proteins, we found
very few peptides (data not shown). The peptide fractions
resulting from HPLC-SCX were collected, pooled, and
subjected to liquid chromatography and tandem mass
spectrometry (LC-MS/MS), and was followed by protein
Figure 3 Summary of the experimental design. See text and abbreviations for more details.
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http://www.clinicalproteomicsjournal.com/content/12/1/1identification and quantification. Experimental details
regarding HPLC-SCX, LC-MS/MS, and protein identifi-
cation and quantification, were previously published
[31], and are also outlined in Additional file 7.Bioinformatic analysis
To detect upregulated proteins in the PsA group, one-
sided Student’s t-tests were used between PsA L and PsC
L, and PsA N and PsC N after log transformation of XIC
values. Only proteins displaying significant differences
[False discovery rate (FDR) <0.2] were used for further
analysis [33]. The FDR threshold was chosen such that if
we repeat the procedure many times, 20% of the signifi-
cant differences are expected to be false, on average. Aver-
ages of the replicate XIC values were calculated for each
PsA L, PsA N, PsC L, and PsC N, and ratios (fold change:
FC) of PsA L/PsC L, and PsA N/PsC N were computed.
Gene names of the upregulated proteins were checked
against gene [BioGPS (http://biogps.org/#goto=welcome)
[34]], and protein [Human Protein Atlas (http://www.
proteinatlas.org/) [35] databases, to identify proteins with
strong expression in PsA-associated tissues and cell types
(skin, bone, immune cells). The Plasma Proteome Data-
base (http://www.plasmaproteomedatabase.org/) [36] was
employed to identify proteins present in high-abundance
in serum, which could represent potential contaminants.
Selected reaction monitoring (SRM) assays were devel-
oped for the top upregulated proteins in the lesional PsA
group and housekeeping (ACTB, TUBB) proteins, and
relative protein quantification was performed in individual
skin samples to confirm their elevation in PsA skin.Verification of identified proteins using SRM
SRM methods were developed for verification of protein
ratios in skin, following our previously published protocols
[23,31]. Details regarding the SRM assay development,
skin sample preparation, and subsequent protein quantifi-
cation are also outlined in Additional file 7.Validation of verified proteins
Enzyme-linked immunosorbent assays (ELISA)
The concentration of ITGB5 in serum was measured using
an in-house developed protocol, the details of which are
outlined in Additional file 7. Serum was diluted 10-fold.
The concentration of POSTN in serum was measured
using a multiplexed Luminex Screening Assay (R&D Sys-
tems), according to manufacturer’s instructions. Serum
was diluted 100-fold.
Statistical analysis
The Student’s t-tests were performed to analyze the LC-
MS/MS data using R statistical software (http://www.r-
project.org/). Other statistical analyses were performed
using Graph Pad Prism v.6.0 for Mac (GraphPad Software,
CA, USA). Results were analyzed using the nonparametric
Mann-Whitney U test. P-values less than 0.05 were consid-
ered statistically significant. Spearman's rank correlation co-
efficient was used to assess the correlations between serum
levels of POSTN, and ITGB5. Concentrations are reported
in the text as mean ± standard deviation (SD).
The overall experimental design is provided in Figure 3.
Additional files
Additional file 1: Table S1. RAW data listing 1922 proteins identified
by LC-MS/MS, in lesional and non-lesional PsA and PsC skin.
Additional file 2: Table S2. Unfiltered list of elevated proteins in
lesional and non-lesional PsA skin, as identified by LC-MS/MS. The red
font represents data and calculations ycorresponding to PsA lesional skin,
while the blue font indicates the PsA non-lesional skin data points and
calculations. Proteins commonly elevated in the lesional and non-lesional
PsA groups are depicted in the last column.
Additional file 3: Table S3. Fold change (FC) of 47 elevated proteins in
PsA skin compared to PsC skin, as identified by LC-MS/MS. *FC represents
the ratio of the mean XIC values of 10 skin samples per group (PsA L vs.
PsC L); **N/A indicates that a ratio could not be compiled since the protein
was absent in PsC skin; ***P-Values were calculated using the student's
t-tests; ****FDR represents the false discovery rate of each protein.
Additional file 4: Table S4. List of 47 filtered and 2 housekeeping
proteins, and the corresponding peptide sequences and transitions that were
monitored in the multiplexed SRM assay. The sequence and transitions of the
spiked-in heavy peptide are also depicted in the last three rows.
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http://www.clinicalproteomicsjournal.com/content/12/1/1Additional file 5: Figure S1. Distribution of markers across the PsA and
PsC skin Set I. Dots represent skin samples from individual subjects; thin
horizontal lines depict the mean, and vertical lines the SD. **** indicates
P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; ns:non-significant.
Additional file 6: Figure S2. Distribution of markers across the PsA and
PsC skin Set II. Dots represent skin samples from individual subjects; thin
horizontal lines depict the mean, and vertical lines the SD. **** indicates
P < 0.0001; ***P < 0.001; **P < 0.01; *P < 0.05; ns:non-significant.
Additional file 7: Supplementary Materials and Methods.
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